Miranda Pablo
ALZAK Foundation, Bolívar, Colombia.
Rev Alerg Mex. 2020 Jan-Mar;67(1):19-24. doi: 10.29262/ram.v67i1.701.
Omalizumab is effective in the treatment of severe persistent allergic asthma that is not controlled with long-acting beta-agonists/ high-dose inhaled corticosteroids.
To conduct a systematic exploratory review and meta-analysis of studies with omalizumab in Latin America.
A search of real-life studies on the effectiveness of omalizumab in asthma control conducted in Latin America was carried out. The average of the aggregate effectiveness of omalizumab in asthma control (Pooled Analysis) was estimated by using a random effects model.
Nine open uncontrolled observational studies were identified; these studies included a total of 1 118 patients with severe uncontrolled asthma. The average of the estimated aggregate effectiveness of omalizumab in the good control of severe asthma was of 80.6 % in children and 78.9 % in adults.
The average of the estimated aggregate effectiveness of omalizumab in the control of severe asthma in both children and adults in Latin America was over 78 %. Randomized controlled studies are required in order to establish the efficacy and effectiveness of omalizumab in the control of severe asthma and in the different subgroups by level of eosinophils.
奥马珠单抗对长效β受体激动剂/高剂量吸入性糖皮质激素治疗效果不佳的重度持续性过敏性哮喘有效。
对拉丁美洲有关奥马珠单抗的研究进行系统的探索性综述和荟萃分析。
检索拉丁美洲开展的关于奥马珠单抗控制哮喘有效性的真实研究。采用随机效应模型估算奥马珠单抗控制哮喘总体有效性的平均值（汇总分析）。
确定了9项开放的非对照观察性研究；这些研究共纳入1118例重度未控制哮喘患者。奥马珠单抗有效控制重度哮喘的总体有效性估算平均值在儿童中为80.6%，在成人中为78.9%。
在拉丁美洲，奥马珠单抗控制儿童和成人重度哮喘的总体有效性估算平均值超过78%。需要开展随机对照研究以确定奥马珠单抗在控制重度哮喘及不同嗜酸性粒细胞水平亚组中的疗效和有效性。
Zotero 插件